Diosgenin-conjugated PCL–MPEG polymeric nanoparticles for the co-delivery of anticancer drugs: design, optimization, in vitro drug release and evaluation of anticancer activity
- 26 March 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 43 (17) , 6622-6635
Abstract
The purpose of the present study was to develop nanoparticulate drug carrier systems for anticancer drugs and evaluate their efficacy by in vitro anticancer assays and release studies. Herein, diosgenin (DGN) was chemically conjugated to the polymeric carrier via a cleavable ester bond. We developed methoxy poly(ethylene glycol) (MPEG) as the shell, DGN conjugated poly(ε-caprolactone) (PCL) as the hydrophobic core as well as amphiphilic block copolymers to design a co-delivery system. The physicochemical properties of the DGN-conjugated PCL–MPEG copolymers were determined by GPC, 1H-NMR, FT-IR, TGA and DSC techniques. Then, Imatinib (ITB) was physically encapsulated by DGN-conjugated PCL–MPEG nanoparticles (NPs) utilizing an emulsion solvent evaporation method. The nanoparticulate formulations were characterized by TEM and DLS. Drug loading and encapsulation efficiency, the in vitro drug release profile, pharmacological evaluation and the stability studies of NPs were investigated. The results showed that the prepared spherical NPs had a uniform particle size (in vitro release profile was influenced by the pH values of the simulated medium and exhibited an initial burst effect followed by a slower and continuous release over a period of 10 days. The in vitro biocompatibility and anticancer activity were evaluated using human fibroblast (L929), leukemia (K-562), osteosarcoma (SAOS-2), and breast carcinoma cells (MCF-7). The cytotoxicity assay showed that the IC50 of ITB-loaded DGN-conjugated NPs were lower compared to the free drugs. Moreover, DGN-conjugated NPs exhibited an obvious synergistic effect by the combination of two anticancer drugs, DGN and ITB. These results suggest that diosgenin-conjugated polymeric NPs may be considered as a promising delivery system for cancer therapy.Keywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
This publication has 56 references indexed in Scilit:
- Preparation and in vivo pharmacokinetics of curcumin-loaded PCL-PEG-PCL triblock copolymeric nanoparticlesInternational Journal of Nanomedicine, 2012
- The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapyChemical Society Reviews, 2012
- Synthesis of Monomethoxypolyethyleneglycol—Cholesteryl Ester and Effect of its Incorporation in LiposomesAAPS PharmSciTech, 2011
- Novel drug delivery systems: Chitosan conjugates covalently attached to steroids with potential anticancer and agrochemical activityCarbohydrate Polymers, 2011
- Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluationInternational Journal of Pharmaceutics, 2010
- Biodegradable self-assembled PEG–PCL–PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterizationNanotechnology, 2010
- Synthesis of 26-hydroxy-22-oxocholestanic frameworks from diosgenin and hecogenin and their in vitro antiproliferative and apoptotic activity on human cervical cancer CaSki cellsBioorganic & Medicinal Chemistry, 2010
- Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of DocetaxelBiomaterials, 2010
- Nanoparticle-based targeted drug deliveryExperimental and Molecular Pathology, 2009
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002